STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Covid19
Interventions
DRUG

Brensocatib

Selective, competitive, and reversible inhibitor of DPP1

DRUG

Placebo

Matched placebo

Trial Locations (16)

Unknown

NHS Grampian, Aberdeen

Royal United Hospitals Bath NHS Foundation Trust, Bath

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Cardiff & Vale University Health Board, Cardiff

NHS Tayside, Dundee

NHS Fife, Dunfermline

Frimley Health NHS Foundation Trust, Frimley

Princess Alexandra Hospital NHS Trust, Harlow

NHS Highland, Inverness

NHS Forth Valley, Larbert

University Hospitals of Leicester NHS Trust, Leicester

Liverpool University Hospitals NHS Foundation Trust, Liverpool

Portsmouth Hospitals NHS Trust, Portsmouth

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

University Hospitals North Midlands NHS Trust, Stoke-on-Trent

NHS Lanarkshire, Wishaw

All Listed Sponsors
collaborator

NHS Tayside

OTHER_GOV

collaborator

Insmed Incorporated

INDUSTRY

lead

University of Dundee

OTHER

NCT04817332 - STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 | Biotech Hunter | Biotech Hunter